Dr. Michael Milosevic, MD
Claim this profileUniversity Health Network
Studies Cervical Cancer
Studies Solid Tumors
5 reported clinical trials
4 drugs studied
Area of expertise
1Cervical Cancer
Stage I
Stage II
Stage III
2Solid Tumors
Affiliated Hospitals
Clinical Trials Michael Milosevic, MD is currently running
FDG-PET
for Cervical Cancer
Nearly all cervical cancers are caused by the human papilloma virus (HPV), which can be detected in cancer tissue by laboratory tests. There is evidence that the virus can also be detected from a blood sample to monitor the effects of treatment. Previous studies have shown that a special test called 18F-Fluorodeoxyglucose (FDG) Positron Emission Tomography/Computed Tomography (PET-CT) at 3 months after treatment may predict survival in cervical cancer. The purpose of this study is to see how well the FDG-PET Scan and blood tests for HPV can detect leftover cervical cancer cells after treatment. This study is not a particular form of treatment and patients will receive standard of care treatment.
Recruiting1 award N/A3 criteria
HyperSight Imaging
for Cancer
This is a prospective, single-arm, single-site study designed to generate data describing the image quality and applicability/useability of a high-performance, on-couch CBCT imaging technology (HyperSight) in patients receiving radiation treatment for cancer on a C-arm linear accelerator (TrueBeam).
Recruiting1 award N/A4 criteria
More about Michael Milosevic, MD
Clinical Trial Related6 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Michael Milosevic, MD has experience with
- 18F-Fluoroazomycin Arabinoside (18F-FAZA)
- Magnetic Resonance-guided Radiation Therapy (MRgRT)
- [18-F]- FDG - PET
- HyperSight
Breakdown of trials Michael Milosevic, MD has run
Cervical Cancer
Solid Tumors
Prostate Cancer
Pelvic Cancer
Neck Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Michael Milosevic, MD specialize in?
Michael Milosevic, MD focuses on Cervical Cancer and Solid Tumors. In particular, much of their work with Cervical Cancer has involved Stage I patients, or patients who are Stage II.
Is Michael Milosevic, MD currently recruiting for clinical trials?
Yes, Michael Milosevic, MD is currently recruiting for 4 clinical trials in Toronto Ontario. If you're interested in participating, you should apply.
Are there any treatments that Michael Milosevic, MD has studied deeply?
Yes, Michael Milosevic, MD has studied treatments such as 18F-Fluoroazomycin Arabinoside (18F-FAZA), Magnetic resonance-guided radiation therapy (MRgRT), [18-F]- FDG - PET.
What is the best way to schedule an appointment with Michael Milosevic, MD?
Apply for one of the trials that Michael Milosevic, MD is conducting.
What is the office address of Michael Milosevic, MD?
The office of Michael Milosevic, MD is located at: University Health Network, Toronto, Ontario M5G 2M9 Canada. This is the address for their practice at the University Health Network.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.